NXTM stock: buy or sell?
June 28th, 2019
NxStage Medical, Inc., a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure.
Should I buy NXTM stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, 2 buy setups match with NxStage Medical stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is NxStage Medical stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for NXTM stock for the last month.
NXTM stock analysis
After several days of continuous hikes in past weeks, NxStage Medical stayed constant 0.00% to $30.00.
NxStage Medical set new all time highs back again on June, marking to $30.00. Shares closed at $30.00 and stayed constant 0.00%. Since price and SMA100d lines crossed up on January, NXTM climbed $1.72 (6.08%).
NxStage Medical touched new all time highs again this week, setting highs to $30.00. Shares ended at $30.00 and stayed stable 0.00% during the week. Late June was the fifth green week in a row.
Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $29.26 resistance. Since price and SMA20w lines crossed up late January, NXTM climbed $1.56 (5.49%).
NXTM stock price history
NXTM IPO was on January 4th, 2018 at $24.56 per share1. Since then, NXTM stock surged a 22.10%, with an average of 22.10% per year. If you had invested right after NXTM's IPO a $1,000 in NXTM stock in 2018, it would worth $221.00 today.
1: Adjusted price after possible price splits or reverse-splits.
NXTM stock historical price chart
NXTM stock reached all-time highs on June with a price of $30.00.
NXTM stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not found any price target for NxStage Medical stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareSince last February, when NxStage Medical posted its last earnings report, it remained steady a tight 0.00%. As soon as we get its posted EPS from the earnings report, we will update this report.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2016, last anual revenues report draw a very good gain of 7.52% to $393.94 M dollars. When comparing 2017 vs 2016, on the other hand, profit margin (that is, the net income divided by revenues) depreciated a -2.25% to -3.55%. NxStage Medical fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, NxStage Medical TTM sales up to December 2018 were $322.39 and earnings $-3.17 M USD. When comparing this TTM figures with the last reported annuality, we can review NxStage Medical business evolution since December 2017: Annual turnover up to December, compared to lastest yearly report, plunged a dreadful -18.16%. Regarding profit margin, NxStage Medical grew 2.57% to -3.55%
|2013||$263 M||-||$-18.56 M-7.0%||-|
|2014||$302 M||14.45%||$-23.95 M-7.9%||29.02%|
|2015||$336 M||11.48%||$-15.34 M-4.6%||-35.93%|
|2016||$366 M||9.00%||$-4.77 M-1.3%||-68.90%|
|2017||$394 M||7.52%||$-13.99 M-3.6%||193.27%|
|TTM||$322 M||-18.16%||$-3.17 M-1.0%||-77.37%|
Quarterly financial resultsNxStage Medical posted million in revenues for 2018-Q4, a -100.00% decline compared to previous quarter. Reported quarter earnings marked M with a profit margin of . Profit margin remained constant a 0.00% compared to previous quarter when profit margin was 0.81%. When comparing revenues to same quarter last year, NxStage Medical sales marked a hair-raising decrease and plummed a -100.00%.
|2016-Q4||$93 M||-||$-1.60 M-1.7%||-|
|2017-Q1||$97 M||4.11%||$-1.19 M-1.2%||-25.63%|
|2017-Q2||$96 M||-0.63%||$-2.09 M-2.2%||75.63%|
|2017-Q3||$97 M||1.12%||$-8.45 M-8.7%||304.07%|
|2017-Q4||$104 M||6.48%||$-2.27 M-2.2%||-73.13%|
|2018-Q1||$107 M||3.57%||$-1.46 M-1.4%||-35.70%|
|2018-Q2||$107 M||-0.31%||$-2.59 M-2.4%||77.45%|
|2018-Q3||$108 M||1.08%||$0.88 M0.8%||-134.03%|
NxStage Medical ownershipWhen you are planning to buy a company, it's worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For NxStage Medical, of all outstanding shares are owned by its staff.
The following table compares ownership indicators for other stocks related to NxStage Medical:
|Market cap||$0.0 M|
|Total shares||0.0 M|
|Float shares||0.0 M|
|- Institutional holdings (%)||0.0%|
|- Insider holdings (%)||0.0%|
|Shares in short selling||0.0%|
|Friday, June 28th, 2019|
|Day range||$29.98 - $30.00|
|Average true range||$0.17|
|50d mov avg||$28.84|
|100d mov avg||$28.59|
|200d mov avg||$28.23|
NxStage Medical performanceTo better understand NxStage Medical performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare NxStage Medical performance to :